More on additives to the EVLP perfusate: MSC-conditioned medium
The use of mesenchymal stromal/stem cell (MSC)-based treatments have been employed increasingly during ex-vivo lung perfusion (EVLP) to alleviate the activation of IRI-mediated processes in the lung.
In an interesting study from Palermo and Pittsburg(11), the paracrine effects of human amnion-derived MSCs (hAMSCs) were investigated in an in vitro model of lung IRI that includes cold ischemia and normothermic EVLP. The authors found that the EVLP perfusate, STEEN solution, enriched by a hAMSC-conditioned medium (hAMSC CM) preserved the viability and delayed the apoptosis of alveolar epithelial cells (A549) through the downregulation of inflammatory factors and the upregulation of antiapoptotic factors. These effects were more evident using the CM of 3D hAMSC cultures, which contained an increased amount of immunosuppressive and growth factors compared to both 2D cultures and encapsulated-hAMSCs.
Many of the benefits of stem-cell based treatments are paracrine – there is very little actual engraftment. So this is an excellent study exploring the role of a cell-conditioned medium in a familiar model, with some intriguing results.
XVIVO Insights PB-2021-04-20
